This invention relates a method of orally administering a liquid consisting of a combination of nitrogen based compounds consisting of nitrogen, nitric oxide or nitrous oxide with amino acids and/or amino acid peptides salts and esters and stimulants and stimulant salts to increase athletic performance, anti-aging focus, and energy output, and a method of administering a combination of combining hydrogen compounds, consisting of hydrogen gases and/or ions including but not limited to H2 and H+ signaling molecules with both D and L forms of amino acids and/or amino acid peptides salts and esters, and stimulants and stimulant salts for providing increased athletic performance via hydration, for increased energy output, and for the reduction of free radical damage.

This invention relates a method of orally administering a liquid consisting of a combination of nitrogen based compounds consisting of nitrogen, nitric oxide or nitrous oxide with amino acids and/or amino acid peptides salts and esters and stimulants and stimulant salts to increase athletic performance, anti-aging focus, and energy output, and a method of administering a combination of combining hydrogen compounds, consisting of hydrogen gases and/or ions including but not limited to H2 and H+ signaling molecules with both D and L forms of amino acids and/or amino acid peptides salts and esters, and stimulants and stimulant salts for providing increased athletic performance via hydration, for increased energy output, and for the reduction of free radical damage.

Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Provided herein is technology relating to treating septic shock and particularly, but not exclusively, to methods and systems for identifying sepsis patients most likely to benefit from L-carnitine treatment.

Provided herein is technology relating to treating septic shock and particularly, but not exclusively, to methods and systems for identifying sepsis patients most likely to benefit from L-carnitine treatment.

A medication delivery device for treatment of a pulmonary disorder in a patient includes an elongate member, an expandable member is coupled to a distal end of the elongate member, and an agent delivery portion coupled to an external surface of the expandable member. The agent delivery portion includes an agent that disrupts nerve activity.

A medication delivery device for treatment of a pulmonary disorder in a patient includes an elongate member, an expandable member is coupled to a distal end of the elongate member, and an agent delivery portion coupled to an external surface of the expandable member. The agent delivery portion includes an agent that disrupts nerve activity.

A method of inhibiting GAPDH with N-methylol transfer agents and/or related compounds.

A method of inhibiting GAPDH with N-methylol transfer agents and/or related compounds.

The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.